Cetera Advisors LLC decreased its position in GlaxoSmithKline plc (NYSE:GSK) by 62.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,924 shares of the pharmaceutical company’s stock after selling 9,688 shares during the quarter. Cetera Advisors LLC’s holdings in GlaxoSmithKline were worth $237,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. 1st Global Advisors Inc. raised its holdings in GlaxoSmithKline by 0.4% in the second quarter. 1st Global Advisors Inc. now owns 5,271 shares of the pharmaceutical company’s stock worth $227,000 after purchasing an additional 19 shares in the last quarter. King Luther Capital Management Corp raised its holdings in GlaxoSmithKline by 1.0% in the second quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock worth $234,000 after purchasing an additional 55 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its holdings in GlaxoSmithKline by 1.9% in the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after purchasing an additional 64 shares in the last quarter. Strategic Global Advisors LLC raised its holdings in GlaxoSmithKline by 0.6% in the second quarter. Strategic Global Advisors LLC now owns 12,179 shares of the pharmaceutical company’s stock worth $525,000 after purchasing an additional 75 shares in the last quarter. Finally, PagnatoKarp Partners LLC raised its holdings in GlaxoSmithKline by 1.4% in the second quarter. PagnatoKarp Partners LLC now owns 5,812 shares of the pharmaceutical company’s stock worth $253,000 after purchasing an additional 80 shares in the last quarter. Institutional investors and hedge funds own 9.83% of the company’s stock.
In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of GlaxoSmithKline stock in a transaction that occurred on Monday, November 6th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 10.00% of the stock is currently owned by company insiders.
Shares of GlaxoSmithKline plc (NYSE GSK) opened at $34.99 on Friday. GlaxoSmithKline plc has a twelve month low of $34.52 and a twelve month high of $44.53. The company has a market capitalization of $86,052.55, a PE ratio of 12.41, a P/E/G ratio of 1.94 and a beta of 0.98. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be issued a $0.5037 dividend. This represents a $2.01 annualized dividend and a yield of 5.76%. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date is Thursday, November 9th. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 163.12%.
TRADEMARK VIOLATION NOTICE: “Cetera Advisors LLC Decreases Holdings in GlaxoSmithKline plc (GSK)” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://sportsperspectives.com/2017/12/17/cetera-advisors-llc-decreases-holdings-in-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.